Do Kim
Stock Analyst at Piper Sandler
(2.01)
# 2,862
Out of 5,182 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $72.23 | -12.78% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $40.81 | +12.72% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $426.01 | -30.52% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $127.75 | -12.33% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $11.74 | +641.06% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.65 | +767.92% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $30.51 | -34.45% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $2.68 | +1,504.48% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $44.65 | -28.33% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $4.16 | +428.85% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $46.29 | -58.95% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.56 | +250.88% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $308.51 | -40.03% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.56 | +25,180.90% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $64.49 | -45.73% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.31 | +1,426.72% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $72.23
Upside: -12.78%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $40.81
Upside: +12.72%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $426.01
Upside: -30.52%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $127.75
Upside: -12.33%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $11.74
Upside: +641.06%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.65
Upside: +767.92%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $30.51
Upside: -34.45%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $2.68
Upside: +1,504.48%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $44.65
Upside: -28.33%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $4.16
Upside: +428.85%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $46.29
Upside: -58.95%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $4.56
Upside: +250.88%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $308.51
Upside: -40.03%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $3.56
Upside: +25,180.90%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $64.49
Upside: -45.73%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.31
Upside: +1,426.72%